TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

(2015) Johanna C. Bendell et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer

(2015) Toshihiko Doi et al.   INVESTIGATIONAL NEW DRUGS

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes

(2015) Chiara Focaccetti et al.   PLoS One

Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history

(2013) Claire Kelly et al.   EUROPEAN JOURNAL OF CANCER

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours

(2012) T Doi et al.   BRITISH JOURNAL OF CANCER

Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced Cardiotoxicity

(2012) Guido Deboever et al.   Clinical Colorectal Cancer

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

(2012) Takayuki Yoshino et al.   LANCET ONCOLOGY

Fluoropyrimidine-associated cardiotoxicity: revisited

(2009) M Wasif Saif et al.   Expert Opinion On Drug Safety

Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors

(2008) Michael J. Overman et al.   INVESTIGATIONAL NEW DRUGS